Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Diane K. Reyes"'
Autor:
Liang Dong, Xinxing Du, Changxue Lu, Zhongyuan Zhang, Chung-Ying Huang, Lei Yang, Sarah Warren, Morgan D. Kuczler, Diane K. Reyes, Jun Luo, Sarah R. Amend, Wei Xue, Kenneth J. Pienta
Publikováno v:
Materials Today Bio, Vol 17, Iss , Pp 100474- (2022)
The application of circulating tumor cells (CTCs) in both clinical practice and research has been continuously limited by the rare number of targets that can be found in a tube of peripheral blood. Diagnostic leukapheresis (DLA) was used to increase
Externí odkaz:
https://doaj.org/article/39e45700bf284dadb256c3d1d9a12200
Autor:
Diane K. Reyes, Shadpour Demehri, Rudolf A. Werner, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe, Kenneth J. Pienta
Publikováno v:
Urology Case Reports, Vol 23, Iss , Pp 72-74 (2019)
We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment p
Externí odkaz:
https://doaj.org/article/0c6a96f3ea37413aa52402e3a24415ba
Publikováno v:
Urology Case Reports, Vol 3, Iss 3, Pp 59-62 (2015)
This case of oligometastatic prostate cancer to the foot highlights the importance of: 1) metastasis remaining high in the differential for unexplained malady, in the setting of a primary cancer, despite an atypical presentation, and 2) comparing seq
Externí odkaz:
https://doaj.org/article/c726b16f12b641d4b2de0da2cf1b16a9
Publikováno v:
The Prostate
Background The purpose of this study is to assess the body composition changes in men with recently diagnosed oligometastatic prostate cancer following neoadjuvant chemohormonal therapy. Further, we evaluated whether CT‐based body composition param
Autor:
Diane K. Reyes, Bruce J. Trock, Phuoc T. Tran, Christian P. Pavlovich, Curtiland Deville, Mohamad E. Allaf, Stephen C. Greco, Daniel Y. Song, Trinity J. Bivalacqua, Misop Han, Alan W. Partin, A. Oliver Sartor, Steven P. Rowe, Kenneth J. Pienta
Publikováno v:
Medical Oncology. 39
Autor:
Diane K, Reyes, Bruce J, Trock, Phuoc T, Tran, Christian P, Pavlovich, Curtiland, Deville, Mohamad E, Allaf, Stephen C, Greco, Daniel Y, Song, Trinity J, Bivalacqua, Misop, Han, Alan W, Partin, A Oliver, Sartor, Steven P, Rowe, Kenneth J, Pienta
Publikováno v:
Medical oncology (Northwood, London, England). 39(5)
Multimodal therapies were combined to eradicate the primary site, metastatic, and micrometastatic disease in men with newly diagnosed, synchronous, oligometastatic prostate cancer. The investigation included companion, phase II studies: total eradica
Autor:
Diane K. Reyes, Sarah Frey, Bruce J. Trock, Xin Li, Michael A. Gorin, Michael DiGianvittorio, Martin G. Pomper, Steven P. Rowe, Rehab Abdallah, Rudolf A. Werner, J. Keith Bleiler, Kenneth J. Pienta
Publikováno v:
Journal of Nuclear Medicine. 61:183-188
Bone metastases in prostate cancer (PCa) have important prognostic significance, and imaging modalities used for PCa staging should have high sensitivity for detecting such lesions. Prostate-specific membrane antigen (PSMA)-targeted PET radiotracers
Autor:
Diane K, Reyes, Kenneth J, Pienta
Publikováno v:
Medical oncology (Northwood, London, England). 38(7)
The aim of the study was to evaluate the feasibility of utilizing peripheral androgen blockade in men with biochemical recurrent castrate-sensitive prostate cancer. A registration study to track outcomes of men with biochemical recurrent castrate-sen
Autor:
Morgan D. Kuczler, Y.K. Cho, Diane K. Reyes, W. Xue, Liang Dong, Zhongyuan Zhang, K. Smith, Kenneth J. Pienta, Sarah R. Amend
Publikováno v:
European Urology Open Science, Vol 19, Iss, Pp e1565-e1566 (2020)
Autor:
Steven P. Rowe, Christian P. Pavlovich, Phuoc T. Tran, Diane K. Reyes, Curtiland Deville, Ashley E. Ross, Mohammad E. Allaf, Kenneth J. Pienta, Edward M. Schaeffer
Publikováno v:
Medical Oncology (Northwood, London, England)
To evaluate the outcomes of total eradication therapy (TET), designed to eradicate all sites of visible cancer and micrometastases, in men with newly diagnosed oligometastatic prostate cancer (OMPCa). Men with ≤ 5 sites of metastases were enrolled